TLIS (Talis Biomedical) Forward PE Ratio: 0.00 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLIS Talis Biomedical Corp TLIS
28 GF Score
Price $2.84
View Full Analysis

What is Talis Biomedical Forward PE Ratio?

Talis Biomedical TLIS 28 Forward PE Ratio is 0.00 as of Jul. 16, 2026. GuruFocus rates TLIS with a GF Score™ of 28/100.

Talis Biomedical's Forward PE Ratio for today is 0.00.

Talis Biomedical's PE Ratio without NRI for today is 0.00.

Talis Biomedical's PE Ratio (TTM) for today is 0.00.

Talis Biomedical  (OTCPK:TLIS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Talis Biomedical Forward PE Ratio Related Terms

Talis Biomedical Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Talis Biomedical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talis Biomedical Forward PE Ratio Chart

Talis Biomedical Annual Data
Trend
Forward PE Ratio

Talis Biomedical Quarterly Data
Forward PE Ratio

TLIS vs BJDX, BBLG, VTAK: Forward PE Ratio Comparison

For the Medical Devices subindustry, Talis Biomedical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talis Biomedical Forward PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Forward PE Ratio falls into.


TLIS
28GF Score
Talis Biomedical Corp TLIS
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talis Biomedical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Talis Biomedical (TLIS) has a Forward PE Ratio of 0.00 as of Jul. 16, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Talis Biomedical and its competitors.
Is Talis Biomedical's Forward PE Ratio too high?
Talis Biomedical's current Forward PE Ratio is 0.00. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's Forward PE Ratio compare to BJDX and BBLG?
Talis Biomedical's Forward PE Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Forward PE Ratio is 19.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.26, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Talis Biomedical and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Talis Biomedical's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current Forward PE Ratio is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Talis Biomedical Business Description

Address 1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score

Get the complete analysis for TLIS

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.84
Price